

Erratum

Single-center developing country analysis of radium-223 therapy in prostate cancer-preliminary results: Am J Nucl Med Mol Imaging. 2021; 11(5): 352-362

Thaís B Minekawa¹, Allan O Santos^{1,2}, André G Moraes³, André Sasse⁴, Cleide A Silva⁵, Marcelo T Lima⁵, Mariana Camacho², Mariana C Lima^{1,2}, Elba Etchebehere^{1,2}

¹Division of Nuclear Medicine of The Department of Radiology, University of Campinas (UNICAMP), Campinas, Brazil; ²Medicina Nuclear de Campinas (grupoMND), Campinas, Brazil; ³Centro de Oncologia Campinas (COC), Campinas, Brazil; ⁴Grupo SONHE, Campinas, Brazil; ⁵Department of Statistics, University of Campinas (UNICAMP), Campinas, Brazil

Received May 8, 2023; Accepted May 9, 2023; Epub June 25, 2023; Published June 30, 2023

In this article, we found an error in the Radium-223 treatment section. The correction should be: Intravenous infusions of 50 kBq/kg (1.4 µCi/kg) of Ra223Cl₂ doses were injected every 6 weeks. Therefore, we would like to publish this Erratum to reflect this change. The authors regret this error.

Address correspondence to: Dr. Elba Etchebehere, Division of Nuclear Medicine of The Department of Radiology, University of Campinas, R. Vital Brasil, 251-Cidade Universitária, Campinas, SP 13083-888, Brazil. Tel: +55-19-997718779; E-mail: elba@hc.unicamp.br